The Notch regulated ankyrin repeat protein (NRARP) is a negative feedback regulator of Notch signaling in higher organisms. The molecular basis for NRARP function, however, has remained elusive. Mass spectrometry-based proteomic studies show that human NRARP associates with the core Notch transcriptional activation complex (NTC), containing the RBPJ transcription factor, the Notch intracellular domain (NICD), and a Mastermind-like co-activator. Binding of NRARP is direct, requires both RBPJ and NICD, and is independent of Mastermind-like proteins or DNA. The X-ray structure of an NRARP/RBPJ/NOTCH1/DNA complex, determined to 3.75 Å resolution, reveals a non-canonical mode of binding in which NRARP extends the NOTCH1 ankyrin-repeat stack by three additional repeats. Mutations of NRARP residues at the binding interface disrupt entry into complexes and suppress feedback inhibition in signaling assays.
Introduction
Cell signaling enables an organism to perceive and respond to its local environment. This fundamental process occurs in a series of tightly regulated steps that require stimulus detection, signal transmission, and a downstream response. The amplitude and duration of the response can be tuned by a variety of signaling modulators, which can vary widely based on the cellular context.
One common mechanism of signal modulation is feedback inhibition, in which the downstream response to the signal produces an output that suppresses the initiating signal. Feedback regulation is particularly important in developmental signaling, where control of the timing and strength of the signal is critical to ensure proper cellular proliferation and differentiation.
Notch signaling is the primary juxtacrine developmental signaling pathway controlling cell fate decisions in multicellular organisms (Bray, 2016) . Mutations of the core components of this pathway give rise to a variety of developmental disorders, including Alagille syndrome (Li et al., 1997) , left ventricular non-compaction (Luxan et al., 2013) , spondylocostal dysostosis (Bulman et al., 2000) , and Hajdu-Cheney syndrome (Isidor et al., 2011; Majewski et al., 2011; Simpson et al., 2011) as well as adult onset diseases such as CADASIL (Joutel et al., 1996) . In addition, aberrant or dysregulated Notch signaling is associated with many different human cancers including T cell acute lymphocytic leukemia (T-ALL), in which activating mutations of the Notch1 receptor are found in more than half of all cases (Aster et al., 2017) . Notch signaling activation depends on cell-cell contact between a ligand-expressing "sender" cell and a receptor-expressing "receiver" cell (Fehon et al., 1990; Rebay et al., 1991) . Ligand binding results in regulated intramembrane proteolysis of the receptor, liberating the intracellular portion of Notch (ICN) from the membrane (De Strooper et al., 1999; Schroeter et al., 1998; Struhl and Greenwald, 1999) . ICN then migrates into the nucleus, and enters into a transcriptional activation complex that includes Notch, the transcription factor RBPJ, and a coactivator protein of the Mastermind-like (MAML) family (Petcherski and Kimble, 2000a; Petcherski and Kimble, 2000b; Wu et al., 2000) , resulting in induced transcription of Notch responsive genes (see (Bray, 2016) for a review).
The Notch regulated ankyrin repeat protein (NRARP) is one of a small number of core Notch target genes. NRARP cDNA was first identified in an in situ hybridization screen following analysis of the Delta1 synexpression group of developmentally expressed genes in Xenopus embryos (Gawantka et al., 1998) . The cDNA was later shown to encode a 114 amino acid protein consisting of at least two tandem C-terminal ankyrin repeats, and to be regulated at the transcriptional level by the Notch signaling pathway in Xenopus and mice (Krebs et al., 2001; Lamar et al., 2001) .
Several studies in different organisms and developmental contexts have reported that NRARP is a negative regulator of Notch signaling. Enforced expression of Nrarp in mice leads to a block in T cell development, which requires Notch signaling at multiple stages (Yun and Bevan, 2003) . In addition, Nrarp knockout mice exhibit defects in somitogenesis and vascular pruning in the eye (Krebs et al., 2012; Phng et al., 2009 ). Both of these phenotypes are associated with excess Notch activity, and, together with studies investigating the influence of Nrarp on cell fate decisions in the mouse retina (Mizeracka et al., 2013) , further support the conclusion that
NRARP counteracts Notch signals in vivo.
The molecular basis for the action of NRARP as a negative regulator of Notch signaling is incompletely understood. Experiments in Xenopus embryos using overexpressed tagged Notch components and NRARP detected association of NRARP with ICN and RBPJ, suggesting that the NRARP protein enters into a complex with the NTC (Lamar et al., 2001) . However, proteomic studies to uncover NRARP-interacting, endogenously expressed proteins have not been performed, nor has an NRARP-NTC complex been reconstituted using purified proteins.
Moreover, there are no structural data available for NRARP or NRARP-containing complexes.
Thus, the molecular basis for the function of NRARP as an attenuator of Notch signal transduction has remained elusive.
Using mass spectrometry of tandem-affinity purified NRARP complexes, we show here that human NRARP associates with endogenous Notch transcription complexes (NTCs) containing Notch1, RBPJ, and a MAML coactivator. Using purified proteins, we find that NRARP binds directly to RBPJ-ICN1 complexes, requiring both RBPJ and ICN for entry into NTCs, but not MAML or DNA. The X-ray structure of a NRARP/RBPJ/ICN1/DNA complex, determined to 3.75 Å resolution, reveals that assembly of NRARP/RBPJ/Notch1 complexes relies on simultaneous engagement of RBPJ and Notch1 in a non-canonical binding mode involving the extension of the Notch1 ankyrin repeat stack by the three ankyrin repeats of NRARP. Interface mutations of NRARP disrupt entry into NTCs and abrogate feedback inhibition in Notch signaling assays. These studies establish the structural basis for NTC engagement by NRARP and provide insights into a critical negative feedback mechanism that regulates Notch signaling.
Results

NRARP inhibits Notch signaling and suppresses growth of Notch-dependent T-ALL cells
Previous studies in Xenopus (Lamar et al., 2001 ) and in mice (Krebs et al., 2012; Krebs et al., 2001; Mizeracka et al., 2013) have implicated NRARP as a negative regulator of Notch signaling (Figure 1 ). To test whether human NRARP inhibits Notch activity in cells, we used a wellestablished luciferase reporter-gene assay (Weng et al., 2003) . Enforced expression of NRARP suppresses reporter activity induced by intracellular Notch1 (ICN1) in a dose-dependent manner ( Figure 1B ), consistent with these prior studies. To test whether the negative regulatory activity of NRARP is selective for ICN1, we also tested the effect of NRARP on reporter gene induction by ICN2, ICN3, and ICN4. The data show that NRARP inhibits reporter gene induction by all four human Notch receptors, although the inhibitory effect on ICN4-dependent reporter activity is not as strong ( Supplementary Fig. S1 ).
Previous studies have shown that genetic and chemical inhibition of Notch in Notch-mutated T-ALL cell lines results in suppression of cell growth. We tested whether enforced expression of NRARP in two Notch-dependent T-ALL cell lines, DND-41 and HPB-ALL, results in growth suppression, as predicted for a negative modulator of signaling. Cells were infected with GFPexpressing retroviruses that were either empty or carried the cDNA for NRARP or dominant-negative MAML1 (Weng et al., 2003) , and the GFP positive populations of unsorted transduced cells were monitored over time to assess the effect of viral transduction on cell growth.
Transduction with NRARP results in suppression of growth of both T-ALL lines to a similar extent as dominant-negative MAML1 (dnMAML), whereas empty virus has no effect ( Figure 1C,   D) . Analysis of the Notch-responsive genes HES1, HES4, and DTX1 in cells expressing NRARP revealed decreased levels of mRNA ( Figure 1E ), again consistent with the conclusion that NRARP is a negative regulator of Notch signaling. The amount of NOTCH1 mRNA, on the other hand, is unchanged in NRARP-expressing cells, suggesting that NRARP regulates NOTCH1 not by influencing its expression, but by modulating its activity at the protein level ( Figure 1E ).
Direct binding of NRARP to NOTCH1-RBPJ complexes requires both RBPJ and
NOTCH1
Previous work carried out in Xenopus embryos using forced expression of tagged proteins showed that NRARP co-immunoprecipitates with Xenopus RBPJ and Xenopus ICN1, suggesting that NRARP enters a complex with Notch and RBPJ (Lamar et al., 2001) . To identify the complete spectrum of proteins that associate with human NRARP, we used tandem affinity purification of HA-FLAG-tagged NRARP from Jurkat cells followed by mass spectrometry of the recovered endogenous proteins. We consistently recovered peptides for the three core components of the NTC: RBPJ, NOTCH1, and MAML1, in four independent experiments (Table 1) . A complete list of all proteins detected in each of these experiments is presented in Supplementary Table 1. RBPJ contains three structured domains that encompass most of the coding sequence, followed by a region that is not required for assembly of RBPJ-ICN1-MAML1 complexes on DNA. ICN1 has a RAM region, a series of ankyrin repeats (ANK), a transcriptional activation region (TAD), and a C-terminal PEST sequence. NRARP is predicted to have three ankyrin repeats, and MAML1 is predicted to be unstructured C-terminal to the region required for formation of the NTC (Figure 2A ).
To map the requirements for formation of complexes between NTC components and NRARP, we purified the RAM-ANK region of NOTCH1 and the structured portion of RBPJ. Neither of these proteins, alone or in combination, form stable complexes with NRARP ( Figure 2B ).
Remarkably, however, extension of the C-terminus of RBPJ to residue 452 enabled purification of stable complexes, but only when both RBPJ and Notch1 are present ( Figure 2B ). Further domain-mapping studies established that the only region of ICN1 that is required for complex formation is the ANK domain ( Figure 2C ), and that association of NRARP with NOTCH1 and RBPJ does not compete with either MAML1 or DNA binding ( Figure 2D ),
Crystal structure of an NRARP-NOTCH1-RBPJ-DNA complex reveals a composite binding interface
To determine the structural basis for recognition of NOTCH1-RBPJ complexes by NRARP, we determined a 3.75 Å X-ray structure of an NRARP-NOTCH1-RBPJ complex bound to DNA, phased using molecular replacement with the human NOTCH1/RBPJ/MAML1/DNA complex (PDB ID code 2F8X; (Nam et al., 2006) ) as a search model ( Table 2 ). The structural features described here are drawn from the better ordered of the two assemblies seen in the asymmetric unit ( Supplementary Figure 2A , B).
The most striking feature of the complex is the assembly of the ankyrin repeats from NOTCH1
and NRARP into a pseudo-continuous stack that wraps around the RBPJ-DNA complex in a crescent-shaped arc ( Figure 3A NRARP itself is a single protein domain with three ankyrin repeats. Even in the structure of the complex, however, the first ankyrin repeat is less ordered that the other two, and its first helix is modeled only as polyalanine even in the better-defined copy of the asymmetric unit. The third ankyrin repeat of NRARP engages the NOTCH1-RBPJ interface at a composite surface that includes the first ankyrin repeat of NOTCH1 and the C-terminal domain of RBPJ. At this interface, NRARP is oriented with its C-terminal ankyrin repeat abutting the N-terminal ankyrin repeat of NOTCH1, thereby creating the pseudo-continuous stack of repeats that travels along the C-terminal Rel-homology domain of RBPJ ( Figure 3A ). The NRARP-NOTCH1 interface results in improved electron density for the first ankyrin repeat of NOTCH1 when compared with the structure of the human NTC, suggesting that NRARP binding stabilizes the structure of this repeat. The interaction between NRARP and RBPJ relies on the canonical concave binding surface of the third ankyrin repeat of NRARP, which appears to approach within contact distance of the C-terminal extension of RBPJ. The interface between NRARP and the NOTCH1-RBPJ complex is non-overlapping with the NOTCH1-RBPJ interface with MAML1, and completely compatible with the observed simultaneous binding of NRARP and MAML1 by RBPJ-Notch complexes on DNA ( Figure 3C ). Moreover, the NRARP binding site is also non-overlapping with the NTC dimerization interface (Arnett et al., 2010) on the convex face of the NOTCH1 ankyrin domain (Supplementary Figure 2C) . Key NRARP residues at the contact interface with NOTCH1-RBPJ include W85 and A92 of the third ankyrin repeat ( Figure 4A ). W85 makes contacts in a cleft created primarily by residues on RBPJ, with an additional potential contact with P1880 of NOTCH1, whereas A92 (stick) of NRARP approaches the first helix of the NOTCH1 ANK domain ( Figure 4B ).
Inhibition of Notch signaling by NRARP depends on the binding interface
To determine whether the inhibition of Notch activity by NRARP relies on the binding interface seen in the X-ray structure, we tested the effect of mutating conserved NRARP residues at this interface in the reporter gene assay. The first mutation, W85E, significantly attenuates the inhibitory effect seen with wild-type NRARP. When combined with an additional A92W mutation (W85E/A92W), the attenuation is even greater ( Figure 5A ). Neither the single nor the double mutation disrupt the overall structural integrity of purified NRARP protein ( Figure 5B ), as judged by the near equivalence of their circular dichroism (CD) spectra ( Figure 5C ). To determine whether the reduced inhibitory activity of the NRARP mutants is indeed due to a decrease in NRARP binding as predicted, we directly tested binding of purified recombinant NRARP polypeptides to RBPJ-NOTCH1 complexes on DNA. Whereas wild-type NRARP enters NOTCH1-RBPJ complexes on DNA, neither W85E nor W85E/A92W do so, confirming that both mutants are defective in forming complexes ( Figure 5D ).
NRARP promotes NOTCH turnover
Prior studies have reported a decrease in detectable levels of ICN when both NOTCH1 and NRARP are transiently co-expressed in Xenopus embryonic extracts (Lamar et al., 2001 ). To determine whether NRARP affects the abundance of endogenous Notch1 in human cells, we infected Jurkat cells with control retrovirus expressing GFP only, virus expressing dnMAML1, or virus expressing NRARP, and probed cell lysates for both total Notch1 and activated Notch1 
Discussion
The induced expression of Notch target genes relies on the formation of an NTC containing the transcription factor RBPJ, ICN, and a MAML coactivator on DNA. The stepwise assembly of an NTC begins with ICN binding to RBPJ, which enables the engagement of MAML followed by the recruitment of additional co-factors for target gene transcription. RBPJ also mediates transcriptional repression in the absence of Notch by interacting with an alternative set of cofactors, including several co-repressors, such as SHARP (Kuroda et al., 2003; Oswald et al., 2002) and KyoT2 (Taniguchi et al., 1998) .
We report here the structure of an NRARP-NOTCH1-RBPJ complex bound to DNA, revealing the molecular basis for interaction of the Notch feedback inhibitor NRARP with the core NTC.
Previous work anticipated the direct interaction of NRARP with Notch-RBPJ complexes from studies with overexpressed proteins in Xenopus extracts (Lamar et al., 2001) . Consistent with those observations, we detected a robust interaction between human NRARP and endogenous components of the core human NTC in Jurkat cells using an unbiased proteomic approach. When we reconstituted a complex with purified proteins, we found that NRARP associates directly with Notch-RBPJ complexes and requires the presence of both Notch and RBPJ for complex formation, much as MAML proteins require both Notch and RBPJ for NTC assembly. Our work with purified proteins also established that a C-terminal extension of RBPJ beyond the region used in previous structural studies is required for stable entry of NRARP into RBPJ-Notch complexes, but that neither MAML nor DNA is needed for NRARP recruitment.
NRARP binding does not induce any major conformational changes in the Notch-RBPJ complex, nor does it interfere with binding of MAML1 or DNA. Instead, NRARP extends the ankyrin repeat stack of Notch1 by three repeats, engaging the first of the NOTCH1 ankyrin repeats with its C-terminal one. NOTCH4, which is the human homolog least sensitive to inhibition in reporter gene assays (Supplemental Figure 1) , also shows the greatest divergence in its first ankyrin repeat, explaining its reduced sensitivity to NRARP inhibition. In contrast, NRARP relies on the concave surface of its ankyrin repeat stack to contact RBPJ, using a binding mode seen frequently in other ankyrin repeat protein complexes. The induced ordering of the C-terminal extension of RBPJ forces the serine/threonine-rich C-terminal segment of RBPJ away from the core of the NTC, potentially exposing it to post-translational modifications that may regulate NTC turnover.
Because NRARP binds to a composite RBPJ-Notch surface, its action is restricted to effector signaling complexes that are engaged in inducing a transcriptional response. Prior work (Fryer et al., 2004) pointed to a link between the assembly of Notch transcription complexes to their timed destruction, with estimates for the half-life of activated (gamma-secretase-cleaved) Notch of roughly 2-4 h. Transcriptional induction of canonical target genes like NRARP in response to activated Notch can occur within 1 h, indicating that negative feedback regulation by direct binding of NRARP to promote Notch turnover may be one of the early steps in the molecular mechanism underlying this "timed destruction" program.
A number of mechanistic explanations may account for why binding of NRARP to the NTC inhibits Notch target gene activation. One possibility is that NRARP binding directly alters the ability of the NTC to recruit co-factors to stimulate transcription, but this explanation seems unlikely because NRARP does not appreciably affect either DNA or MAML binding. Another possibility is that bound NRARP recruits enzymes that directly modify the NTC to suppress transcriptional induction. Along these lines, there are phosphorylation sites near the NRARP binding site on NOTCH1 (Ranganathan et al., 2011) . Though these sites (T1898 and S1901) are distant from the DNA contact interface on RBPJ and unlikely to directly affect DNA binding when modified, their phosphorylation could indirectly affect the ability of NTCs to stimulate transcription. The most likely model for NRARP action, however, supported both by data presented here ( Figure 6A ) and by complementary studies using Xenopus extracts (Lamar et al., 2001) , is that NRARP accelerates NTC turnover ( Figure 6B ), likely by promoting such posttranslational modifications of Notch, as well as of RBPJ and/or MAML. The molecular pathway for NRARP-mediated NTC turnover, which appears to be present in both physiological and pathological contexts, could be a future avenue for development of therapeutics designed to modulate the dynamic response of cells to Notch pathway activation.
Materials and Methods
Protein expression and purification. Wild type and mutant full length NRARP constructs were assembled into a pETHSUL vector at BamHI and XhoI sites to produce His-SUMO fusion molecules. A cassette encoding full-length biotinylated NRARP was assembled by placing a biotinylation (avi) tag between the SUMO tag and NRARP. This cassette was inserted into a pETDUET vector encoding biotin ligase (BirA) for NRARP expression and in-cell biotinylation.
Point mutants were constructed by site-directed mutagenesis.
For protein production, expression constructs were transformed into Rosetta(DE3)pLysS cells and cells were grown in rich media at 18⁰C. Protein expression was induced with 0.5 mM isopropyl β-D-1 thiogalactopyranoside (IPTG), and cells were grown for an additional 16 h at 18⁰C. Cells were harvested by centrifugation, subjected to a freeze-thaw cycle, and lysed by sonication in 50 mM Tris buffer, pH 8.0, containing 500 mM NaCl, 5% glycerol, and 2mM tris(2-carboxyethyl)phosphine (TCEP), and supplemented with EDTA-free protease inhibitor tablets (Roche).
NRARP protein was affinity-captured from cleared lysates by affinity chromatography using HisPur Ni-NTA resin (Thermo Scientific). NRARP was cleaved from the His-SUMO tag and released from the beads using Ulp1 protease. The NRARP protein was then purified by anion exchange chromatography on Mono-Q resin using a linear gradient of NaCl (0.05-1 M) in 20 mM Tris buffer, pH 8.0, containing 1 mM EDTA and 5 mM DTT. Fractions containing the partially purified NRARP protein were combined, concentrated and further purified by sizeexclusion chromatography using a Superdex 200 column equilibrated in 20 mM Tris buffer, pH 8.5, containing 500 mM NaCl, 5% glycerol and 2 mM TCEP. Fractions that were >95% pure as assessed by SDS-PAGE were pooled, flash frozen, and stored at -80⁰ C.
RBPJ molecules (9-452 and 9-435) were expressed and purified using the same series of chromatographic steps. The only modification was the buffer used for anion exchange on Mono-Q resin. Because RBPJ is not stable in low-salt buffer, the linear gradient of NaCl was from 0.1-1 M in 20 mM Tris buffer, pH 8.3, containing 5 mM DTT. MAML1, Notch1 ANK and Notch1 RAMANK proteins were expressed and purified as previously reported (Nam JBC).
Crystallization and Data collection. The components used to generate protein complexes for crystallography were full-length human NRARP, residues 1760-2126 of human Notch1 (comprising the RAM and ANK domains) and residues 9-452 of human RBPJ. Complexes were purified by size exclusion chromatography using a Superdex 200 column equilibrated in 10 mM Hepes buffer, pH 7.8, containing 150 mM NaCl and 2 mM TCEP. A 16mer oligomeric DNA duplex containing an RBPJ binding site with two nucleotide overhangs was generated by annealing oligonucleotides (5'-TTGACTGTGGGAAAGA-3', 5'-AATCTTTCCCACAGTC-3') at 95 ⁰C for 5 minutes and slowly cooling to room temperature. The trimeric protein complex and DNA were combined in a ratio of 1:1.1. Crystals of protein-DNA complex (4 mg/ml) grew in sitting drops at 16 ⁰C after 24-36 hours in 50 mM Hepes pH 6. Quantitative PCR. Total RNA was recovered from Jurkat cells using an RNAeasy Mini Kit (Qiagen), and cDNA was prepared using an iScript cDNA synthesis kit (BioRad). qPCR for NOTCH1, HES1, HES4 and DTX1 was carried out using a CFX384 Real-Time PCR Detection System. Gene expression was normalized to 28s rRNA as an endogenous control.
Proteomics Studies: Tandem Affinity Purification. Jurkat cells were transduced with a retrovirus encoding NRARP preceded by an N-terminal tandem HA-FLAG tag and an internal ribosomal entry site (IRES) followed by the coding sequence for the interleukin-2 receptor (IL2R) (pOZ-FH-N) (Nakatani and Ogryzko, 2003) . Stable cell lines were generated by magnetic sorting for IL2R-positive cells. For proteomic studies, the resulting cell line was grown in RPMI with 10% bovine growth serum to a density of 3x10 6 cells/ml and harvested by centrifugation.
Cells were lysed with a Dounce homogenizer, and the resulting lysate was immunoprecipitated using anti-FLAG-conjugated agarose beads (Sigma) in a 50 mM Tris buffer, pH 7.5, containing 150 mM NaCl, 1 mM EDTA, 0.5% NP40, 2 mM TCEP and 10% glycerol, supplemented with EDTA-free protease inhibitor tablets (Roche). The beads were washed three times and the immunoprecipitated protein was eluted with a 1xFlag peptide. The eluate was then reimmunoprecipitated with anti-HA-conjugated agarose beads and eluted from the beads with HA peptide for mass spectrometry analysis.
Mass spectrometry. Protein complexes isolated by tandem affinity purification (Adelmant et al., 2019) were directly processed in solution: Cysteine residues were first reduced with 10 mM dithiothreitol for 30 minutes at 56°C in the presence of 0.1% RapiGest SF (Waters, Milford, MA) and then alkylated with 22.5 mM iodoacetamide for 20 minutes at room temperature in the dark. Proteins were digested overnight at 37°C using 2.5 micrograms of trypsin after adjusting the pH to 8.0 with Tris.
RapiGest SF was cleaved for 30 minutes at 37°C and its by-products were removed by centrifugation. Tryptic peptides were desalted by batch-mode reverse phase solid phase extraction (Poros 10R2) and concentrated in a vacuum concentrator. Peptides were solubilized in 25% acetonitrile containing 0.1% formic acid and further purified by strong cation exchange (Poros 10HS). Peptides were eluted with 25% acetonitrile containing 0.1% formic acid and 300 mM potassium chloride. Acetonitrile was removed using a vacuum concentrator and peptides were reconstituted with 20 µL of 0.1% TFA.
Peptides were loaded onto a precolumn (4 cm POROS 10R2, Applied Biosystems) and eluted with an HPLC gradient (NanoAcquity UPLC system, Waters; 5%-40% B in 90 min; A = 0.2 M acetic acid in water, B = 0.2 M acetic acid in acetonitrile). Peptides were resolved on a selfpacked analytical column (50 cm Monitor C18, Column Engineering) and introduced in the mass spectrometer (QExactive HF mass spectrometer, Thermo, Waltham, MA) equipped with a Digital PicoView electrospray source platform (New Objective, Woburn, MA) (Ficarro et al., 2009 ).
The mass spectrometer was operated in data dependent mode where the top 10 most abundant ions in each MS scan were subjected to high energy collision induced dissociation (HCD, 30% normalized collision energy) and subjected to MS2 scans (isolation width = 1.6 Da, intensity threshold = 2e 5 ). Dynamic exclusion was enabled with an exclusion duration of 15 seconds. ESI voltage was set to 3.8 kV.
MS spectra were recalibrated using the background ion (Si(CH3)2O)6 at m/z 445.12 +/-0.03 and converted into a Mascot generic file format (.mgf) using multiplierz scripts (PMID: 19333238; PMID: 19874609) . Spectra were searched using Mascot (version 2.6) against three appended databases consisting of: i) human protein sequences (downloaded from RefSeq on 11/19/2010);
ii) common lab contaminants and iii) a decoy database generated by reversing the sequences from these two databases. For Mascot searches, precursor tolerance was set to 15 ppm and product ion tolerance to 25 mmu. Search parameters included trypsin specificity, up to 2 missed cleavages, fixed carbamidomethylation (C, +57 Da) and variable oxidation (M, +16 Da). Spectra matching to peptides from the reverse database were used to calculate a global false discovery rate and were discarded. Data were further processed to remove peptide spectral matches (PSMs)
to the forward database with an FDR greater than 1.0%. Peptides shared by two or more genes were excluded from consideration when constructing the final protein list. Any protein identified in more than 1% of 108 negative TAP controls or any of the negative control TAP experiments (PMID: 22810586) was removed from the sets of interactors.
In vitro biotin pull-down assays. Biotin pull-down assays were performed using streptavidinconjugated agarose (Thermo Fisher) in 20 mM HEPES buffer, pH 7.6, containing 150 mM NaCl, 2 mM TCEP and 0.2% Tween-20. Purified recombinant biotinylated-NRARP, RBPJ and ICN1
(ANK or RAM-ANK) proteins were combined with streptavidin beads at 2 µM and incubated for 30 minutes at room temperature. The beads were washed three times, transferred into gel loading buffer, and the recovered molecules were analyzed by SDS-PAGE using a 4-20% gradient gel followed by staining with Coomassie blue. 
